Skip to main content
Premium Trial:

Request an Annual Quote

Roche, ACC Start Biomarker Web Portal

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Roche Diagnostics is collaborating with the American College of Cardiology to develop a web portal that will be a clinical resource for peer-reviewed biomarker information.

The resource will be accessed through ACC's CardioSource website, and it will be supported by Roche, the ACC said Tuesday.

The collaboration initially will include collections of case studies by experts and peer-reviewed journal articles, and future plans for the resource include forums where physicians can interface with experts in the field and gain knowledge they can use in their practices.

"The goal is to address a need in the medical community for information about biomarkers that is both clinically relevant and scientifically fair and balanced," Roche Professional Diagnostics CMO James Creeden said. "We are excited about this innovative resource because we believe it will give clinicians the independent information they need to practice evidence-based medicine and improve patient care."

"I know of no other resource where physicians can access the latest information about biomarkers and apply them to clinical practice in real time," ACC CEO Jack Lewin added in the statement.

The Scan

Removal Inquiry

The Wall Street Journal reports that US lawmakers are seeking additional information about the request to remove SARS-CoV-2 sequence data from a database run by the National Institutes of Health.

Likely to End in Spring

Free lateral flow testing for SARS-CoV-2 may end in the UK by next spring, the head of Innova Medical Group says, according to the Financial Times.

Searching for More Codes

NPR reports that the US Department of Justice has accused an insurance and a data mining company of fraud.

Genome Biology Papers on GWAS Fine-Mapping Method, COVID-19 Susceptibility, Rheumatoid Arthritis

In Genome Biology this week: integrative fine-mapping approach, analysis of locus linked to COVID-19 susceptibility and severity, and more.